BAJAJ BROKING
Biocon Ltd announced its subsidiary’s approval from NMPA China for Tacrolimus capsules. The drug will strengthen its portfolio and bolster its global market presence. Biocon Ltd share price rose by 1.13% post-announcement.
Biocon Pharma Ltd, a wholly owned subsidiary of Biocon Ltd, has received approval from the National Medical Products Administration (NMPA) in China for its Tacrolimus capsules in strengths of 0.5mg, 1mg, and 5mg. Tacrolimus, an immunosuppressant drug, is primarily used to prevent organ rejection in transplant patients by modulating the immune system.
Also read: Avenue Supermarts Reports 17.5% Revenue Growth in Q3 FY25
Approval Scope: Tacrolimus capsules approved in 0.5mg, 1mg, and 5mg strengths.
Therapeutic Use: Prevents organ rejection in transplant patients.
Global Presence: Enhances Biocon’s portfolio in complex drugs.
Also read: Wockhardt’s Miqnaf Gains CDSCO Approval for CABP Treatment
Metric | Q2 FY25 | Q2 FY24 | Change (YoY) |
Net Profit | ₹27.1 crore | ₹172 crore | -84.2% |
Revenue from Operations | ₹3,590.4 crore | ₹3,462 crore | +3.7% |
EBITDA | ₹685.5 crore | ₹741.3 crore | -7.6% |
This approval marks a strategic milestone for Biocon, as it further strengthens the company’s portfolio of complex drugs and expands its reach in the global pharmaceutical market. With the Chinese market’s regulatory clearance, Biocon can expedite the commercialisation of Tacrolimus capsules in the region.
Following the announcement, Biocon Ltd share price increased by 1.13%, closing at ₹372.95 on the BSE. This reflects investor confidence in Biocon’s ongoing efforts to expand its global footprint and enhance its portfolio.
Biocon’s NMPA approval for Tacrolimus capsules demonstrates its commitment to innovation and global expansion. The move further cements Biocon’s position as a leader in the biotechnology and pharmaceutical sectors, with promising prospects for future growth.
Also read: IRFC Partners REMCL to Fund Renewable Energy for Railways
Do you have a trading account app or demat account app?
You can open an account with Bajaj Broking in minutes.
Download the Bajaj Broking app now from Play Store or App Store.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading